US 12,459,973 B2
Peptide compounds for reducing side effects of CB1 receptor agonists
Vicent Casadó Burillo, Barcelona (ES); Estefania Moreno Guillén, Barcelona (ES); Rafael Maldonado López, Barcelona (ES); David Andreu Martínez, Barcelona (ES); Maria Gallo, Barcelona (ES); Leonardo Pardo Carrasco, Barcelona (ES); Miguel Castanho, Lisbon (PT); Vera Neves, Lisbon (PT); and Marco Cavaco, Lisbon (PT)
Assigned to UNIVERSITAT DE BARCELONA, Barcelona (ES); UNIVERSITAT POMPEU FABRA, Barcelona (ES); UNIVERSITAT AUTONOMA DE BARCELONA, Barcelona (ES); INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES, Lisbon (PT); and FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA, Lisbon (PT)
Appl. No. 17/766,355
Filed by UNIVERSITAT DE BARCELONA, Barcelona (ES); UNIVERSITAT POMPEU FABRA, Barcelona (ES); UNIVERSITAT AUTÒNOMA DE BARCELONA, Barcelona (ES); INSTITUTO DE MEDICINA MOLECULAR JOÃO LOBO ANTUNES, Lisbon (PT); and FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA, Lisbon (PT)
PCT Filed Oct. 2, 2020, PCT No. PCT/EP2020/077642
§ 371(c)(1), (2) Date Apr. 4, 2022,
PCT Pub. No. WO2021/064165, PCT Pub. Date Apr. 8, 2021.
Claims priority of application No. 19382856 (EP), filed on Oct. 3, 2019.
Prior Publication US 2024/0059737 A1, Feb. 22, 2024
Int. Cl. C07K 7/08 (2006.01); A61P 25/02 (2006.01); A61P 25/28 (2006.01)
CPC C07K 7/08 (2013.01) [A61P 25/02 (2018.01); A61P 25/28 (2018.01)] 9 Claims
OG exemplary drawing
 
1. A compound of formula (I)
(I)
AA1-AA2-D-Ile-D-Tyr-AA3-D-Tyr-D-Ala-D-Tyr-D-
 
Val-D-Ala-Gly-D-Ile-D-Leu-D-Lys-D-Arg-D-Trp-NH2
wherein
AA1 represents an amino acid selected from the group consisting of D-Tryptophan (D-Trp), D-1-naphthylalanine (D-1-Nal) and D-2-naphthylalanine (D-2-Nal);
AA2 represents an amino acid selected from the group consisting of D-Leucine (D-Leu), D-Norleucine (D-Nle) and D-Phenylalanine (D-Phe); and
AA3 represents an amino acid selected from the group consisting of D-Methionine (D-Met) and D-Norleucine (D-Nle)
or a pharmaceutically acceptable salt thereof.